

BIONOVELUS, INC.

A Nevada Corporation

Quarterly Report

For Quarter Ending June 30, 2015

1) The exact name of the issuer and its predecessor (if any)

BioNovelus, Inc.

Firstin Wireless Technology, Inc. (until May 15, 2015)

Formerly Passionate Pet, Inc. (until January 31, 2013)

2) The address of the issuer's principal executive offices

15560 N. Frank Lloyd Wright Blvd.

Suite B4-421

Scottsdale, AZ 85260

TEL: 602-881-0438

Website: www.bionovelus.com

3) Security Information

Trading Symbol: ONOV

Exact title and class of securities outstanding: Common

CUSIP: 09073X100

Par or Stated Value: \$0.001

Total shares authorized: 500,000,000 as of: June 30, 2015

Total shares outstanding: 70,116,467 as of: June 30, 2015

Exact title and class of securities outstanding:

Preferred CUSIP: None

Par or Stated Value: \$0.001

Total shares authorized: 10,000,000 as of: June 30, 2015

Total shares outstanding: 10,000,000 as of: June 30, 2015

Transfer Agent

VStock Transfer,

LLC

77 Spruce Street, Suite 201

Cedarhurst, NY 11516

Phone: 212-828-8436

Toll-Free: 855-VSTOCK

Fax: 646-536-3179

info@vstocktransfer.com

VStock Transfer LLC is registered with the Securities and Exchange Commission as a transfer agent pursuant to Section 17A(c) of the Exchange Act.

No restrictions on the transfer of security.

No trading suspension orders issued by the SEC in the past 12 months.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On January 22, 2013 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Passionate Pet, Inc. to Firstin Wireless Technology, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 250 basis which was effected on January 31, 2013. On March 30, 2015 the Company filed a Certificate of Amendment to Articles of Incorporation with the

state of Nevada changing its name from Firstin Wireless Technology, Inc. to BioNovelus, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 750 basis.

Issuance History

During the year 2013, the Company issued common shares as described below:

- 54,417,656 shares of common stock pursuant to the exchange agreement with Firstin Wireless Technology, Inc.
- 32,500,000 common shares for elimination of debt to noteholder

During the year 2014, the Company issued common shares as described below:

- Issued 12,187,500 common shares for elimination of debt to noteholder
- Issued 10,000,000 preferred shares for elimination of debt to noteholder

During the year 2015, the Company issued common shares as described below:

- 70,000,000 shares of common stock pursuant to the agreement with BioNovelus, Inc.

All shares issued contained a restricted legend stating that the shares have not been registered under the Securities Act and this legend further set forth the restrictions on transferability and sale of the shares under the Securities Act.

4) Financial Statements

The Issuer is providing the following financial statements for the quarter ending June 30, 2015 and financial notes, both of which were filed with OTCMarkets on August 21, 2015. These unaudited financial statements and financial notes are incorporated by reference herein.

5) Describe the Issuer's Business, Products and Services

The Company operated a retail pet and supply store in Irvine, California which ran its operations and also sold retail premium pet food, supplies and service to the general public, through a wholly owned subsidiary until the lessor of the building evicted the Company on January 16, 2012. The eviction caused the discontinuation of operations in that location. The Company decided to dispose of this business unit primarily because it has incurred significant operating losses in each of the last two years as the operations could not generate enough revenues to satisfy the significant rent and occupancy costs in the last two years. On July 31, 2012, the former CEO, John Dunn entered into an agreement with the Company to sell 100% of his interest in the Company and assume the net assets and liabilities of the wholly owned subsidiary. As a result, the subsidiary together with its assets and liabilities were wholly owned by Mr. Dunn.

On January 23, 2013, the Company entered into a Share Exchange Agreement with the Firstin Wireless Technology, Inc., a corporation formed under the laws of Canada (Firstin Canada), and the shareholders of Firstin Canada. Under the terms of this agreement, Firstin Canada will become the wholly owned subsidiary of the Company. On April 22, 2015, the Company entered into an Amalgamation Agreement with BioNovelus, Inc., an Arizona corporation.

The following business description and discussion regarding products relates to the operations of BioNovelus, Inc.

A. Description of the issuer's business operations

BioNovelus is a Clean Tech company whose vision is to answer critical environmental problems and to replace harmful chemicals with eco-friendly and profitable technologies in respect to our planet. Its mission is to offer proprietary disruptive green technologies that are innovative, cost-effective solutions for BioNovelus' customers, and partners, and benefit the shareholders and the planet at large.

There is an urgent need to keep ahead of both current and future pathogens, viruses and bacteria as well their resistant superbugs, and invasive species. Current products, many of which are toxic, while effective against many of these dangerous microbes, are corrosive, unstable, dangerous for transportation and for the environment, and cannot prevent re-infection. At BioNovelus, we passionately believe that "in this 21st Century it is time for harmful toxic chemicals to finally be replaced by new generations of eco-friendly, effective, and economical solutions to treat our water and our food."

B. The Company was incorporated in the State of Arizona on September 10, 2010.

C. The Issuer's primary SIC Code is 7389.

D. The Issuer's fiscal year end date is September 30th.

E. The Company's principal products or services, and their markets:

BioNovelus is a Clean Tech company whose vision is to answer critical environmental problems and to replace harmful chemicals with eco-friendly and profitable technologies in respect to our planet. Its mission is to offer proprietary disruptive green technologies that are innovative, cost-effective solutions for BioNovelus' customers, and partners, and benefit the shareholders and the planet at large.

There is an urgent need to keep ahead of both current and future pathogens, viruses and bacteria as well their resistant superbugs, and invasive species. Current products, many of which are toxic, while effective against many of these dangerous microbes, are corrosive, unstable, dangerous for transportation and for the environment, and cannot prevent re-infection. At BioNovelus, we passionately believe that "in this 21st Century it is time for harmful toxic chemicals to finally be replaced by new generations of eco-friendly, effective, and economical solutions to treat our water and our food."

Market

The Biocide space was \$7.2 billion in 2010, and is expected to reach \$9.4 billion in 2016 at a CAGR of 4.3%. BionoPLUS, a biocide and fungicide, is a fast acting disinfectant. This biodegradable product is non-toxic, resistant to high temperatures, flocculent, and non-corrosive. This formula has been tested to also be a proven solution to fight certain invasive species. BionoPLUS available markets for commercialization are Water Treatment; Municipal Waste Treatment; Hydro-electric industry; Aquaculture, and Agricultural Treatment.

The Company is headquartered at 15560 N. Frank Lloyd Wright Blvd, Suite B4-421, Scottsdale AZ 85260. No rental agreement is in place at this location.

6) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

<u>Name</u>	<u>Position</u>	<u>Share Ownership</u>
Jean Ekobo	CEO, Chairman	36,050,000 (51%)

Nathalie Ekobo	Director of Marketing	21,000,000 (30%)
Joss Francheterre	Director	3,850,000 (5%)
Genesis Partners, LLC	Control Person	10,000,000 preferred (votes 85% of all common)
Richard Hess	Secretary	700,000 (<1%)
Marvin Clark	Director & Treasurer	N/A
Iain Glass	Director	N/A
Scott Yenglin	SVP	1,750,000 (2.5%)
Frederick F. Taylor	Director & General Counsel	N/A

B. Legal/Disciplinary History.

None of the foregoing persons mentioned in Item 8, Paragraph A hereinabove have, in the last five years, been the subject of: (1) a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding a traffic violation and other minor offenses; (2) The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or banking activities; (3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities & Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed; (4) The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders.

	<u>Name</u>	<u>Amount</u>	<u>Percent</u>
Common Stock	Jean Ekobo 15560 N. Frank Lloyd Wright Blvd Suite B4-421 Scottsdale AZ 85260	36,050,000	51%
Common Stock	Nathalie Ekobo 15560 N. Frank Lloyd Wright Blvd Suite B4-421 Scottsdale AZ 85260	21,000,000	30%
Common Stock	Joss Francheterre 1202 N. Sailors Way Scottsdale AZ 85260	3,850,000	5%

7) Third Party Providers

Legal Counsel

Frederick F. Taylor

5030 E. Sunrise Dr
Phoenix AZ 85044
TEL: (480)626-0170

Accounting

Dolores Sheets
Tax Accounting Solutions
18918 Road 22
Lewis CO 81327
TEL: (970) 739-9154

8) Issuer Certification

I, Jean Ekobo, certify that:

1. I have reviewed this Quarterly Report of BioNovelus, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: August 21, 2015

/s/ Jean Ekobo
Jean Ekobo
President